It's time to increase testing for this major cardiovascular risk factor in advance of new therapies
Undetectable levels achieved for nearly nine months in phase 1 trial
Targeted mRNA blocking could be first effective approach specific to this cardiovascular risk factor
New phase 2 data boost hopes for phase 3 Lp(a) HORIZON trial
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Cholesterol guideline, vitamin D, REDUCE-IT and lipoprotein(a)